Rut Porta

8.8k total citations
17 papers, 527 citations indexed

About

Rut Porta is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Rut Porta has authored 17 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 7 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Rut Porta's work include Lung Cancer Treatments and Mutations (6 papers), Cancer, Lipids, and Metabolism (5 papers) and Inflammatory mediators and NSAID effects (3 papers). Rut Porta is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer, Lipids, and Metabolism (5 papers) and Inflammatory mediators and NSAID effects (3 papers). Rut Porta collaborates with scholars based in Spain, United States and Italy. Rut Porta's co-authors include Teresa Puig, Javier A. Menéndez, Joan Brunet, Adriana González, David H. Johnson, David P. Carbone, Aung Naing, Roberto Borea, Peter A. van Dam and Tindara Franchina and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of the New York Academy of Sciences.

In The Last Decade

Rut Porta

17 papers receiving 519 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rut Porta Spain 9 289 163 121 114 112 17 527
Marco Rosetti Italy 14 240 0.8× 100 0.6× 86 0.7× 141 1.2× 88 0.8× 28 486
Dianren Xia United States 10 314 1.1× 120 0.7× 76 0.6× 114 1.0× 46 0.4× 17 487
Dean J. Welsch United States 13 313 1.1× 188 1.2× 60 0.5× 158 1.4× 38 0.3× 22 686
Xiuling Li China 14 228 0.8× 145 0.9× 50 0.4× 108 0.9× 82 0.7× 29 468
Labile Togba Soumaoro Japan 6 140 0.5× 101 0.6× 170 1.4× 134 1.2× 42 0.4× 7 405
Kanae Echizen Japan 11 280 1.0× 147 0.9× 56 0.5× 147 1.3× 55 0.5× 14 544
S. Noura Japan 9 168 0.6× 59 0.4× 98 0.8× 176 1.5× 116 1.0× 14 452
Shigeru Tomozawa Japan 8 144 0.5× 155 1.0× 249 2.1× 144 1.3× 65 0.6× 12 521
Wenjie Zhang China 17 407 1.4× 193 1.2× 38 0.3× 120 1.1× 115 1.0× 47 649
Peiyan Hua China 15 367 1.3× 199 1.2× 41 0.3× 87 0.8× 65 0.6× 31 560

Countries citing papers authored by Rut Porta

Since Specialization
Citations

This map shows the geographic impact of Rut Porta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rut Porta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rut Porta more than expected).

Fields of papers citing papers by Rut Porta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rut Porta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rut Porta. The network helps show where Rut Porta may publish in the future.

Co-authorship network of co-authors of Rut Porta

This figure shows the co-authorship network connecting the top 25 collaborators of Rut Porta. A scholar is included among the top collaborators of Rut Porta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rut Porta. Rut Porta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Martín, Andrés J. Muñoz, Marta García de Herreros, Eva Martínez de Castro, et al.. (2024). External validation of a bleeding risk assessment model developed with natural language processing and machine learning (PREDICT-AI study) in patients with anticoagulated cancer with venous thromboembolism in the TESEO international prospective registry.. Journal of Clinical Oncology. 42(16_suppl). e24123–e24123. 1 indexed citations
2.
Porta, Rut, et al.. (2022). AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models. Biomedicine & Pharmacotherapy. 156. 113942–113942. 12 indexed citations
3.
Rabionet, Marc, Sònia Palomeras, Rut Porta, et al.. (2021). Polycaprolactone Electrospun Scaffolds Produce an Enrichment of Lung Cancer Stem Cells in Sensitive and Resistant EGFRm Lung Adenocarcinoma. Cancers. 13(21). 5320–5320. 8 indexed citations
4.
Porta, Rut, Roberto Borea, Shahanavaj Khan, et al.. (2017). FGFR a promising druggable target in cancer: Molecular biology and new drugs. Critical Reviews in Oncology/Hematology. 113. 256–267. 159 indexed citations
5.
Bosch‐Barrera, Joaquim, J. Marruecos, Elisabet Cuyàs, et al.. (2016). Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget. 7(22). 32006–32014. 39 indexed citations
6.
Bosch‐Barrera, Joaquim, Rut Porta, Rafael Fuentes, et al.. (2015). Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression.. PubMed. 35(9). 4871–5. 11 indexed citations
7.
Saurí, Tamara, Á. Izquierdo, Lluís Ramió‐Torrentà, et al.. (2015). Paraneoplastic Limbic Encephalitis in a Male with Squamous Cell Carcinoma of the Lung. Journal of Clinical Neurology. 11(1). 87–87. 2 indexed citations
8.
Bosch‐Barrera, Joaquim, Carol Lorencio, Rut Porta, et al.. (2014). Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. Lung Cancer. 86(1). 102–104. 20 indexed citations
9.
Porta, Rut, Adriana Blancafort, Joan Dorca, et al.. (2013). Fatty acid synthase expression is strongly related to menopause in early-stage breast cancer patients. Menopause The Journal of The North American Menopause Society. 21(2). 188–191. 13 indexed citations
10.
Viñas, Gemma, Teresa Puig, & Rut Porta. (2012). Estrés oxidativo en pacientes con cáncer: dos caras de una misma moneda. Medicina Clínica. 139(4). 171–175. 6 indexed citations
11.
Gascó, Amaya, Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, et al.. (2012). Association of p53 mutations with progression-free survival (PFS) and overall survival (OS) in EGFR-mutated non-small cell lung cancer (NSCLC) patients (p) treated with erlotinib.. Journal of Clinical Oncology. 30(15_suppl). e18143–e18143. 3 indexed citations
12.
Bugés, Cristina, Rafael Rosell, A. Vergnenègre, et al.. (2012). Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study.. Journal of Clinical Oncology. 30(15_suppl). 7542–7542. 2 indexed citations
13.
Rosell, Rafael, Teresa Morán, Felipe Cardenal, et al.. (2010). Predictive biomarkers in the management of EGFR mutant lung cancer. Annals of the New York Academy of Sciences. 1210(1). 45–52. 7 indexed citations
14.
Puig, Teresa, Rut Porta, & Rámón Colomer. (2009). Sintasa de ácidos grasos como nueva diana antitumoral. Medicina Clínica. 132(9). 359–363. 7 indexed citations
15.
Yang, Li, Joseph M. Amann, Takefumi Kikuchi, et al.. (2007). Inhibition of Epidermal Growth Factor Receptor Signaling Elevates 15-Hydroxyprostaglandin Dehydrogenase in Non–Small-Cell Lung Cancer. Cancer Research. 67(12). 5587–5593. 50 indexed citations
16.
Puig, Teresa, Alejandro Vázquez‐Martín, Joana Relat, et al.. (2007). Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Research and Treatment. 109(3). 471–479. 100 indexed citations
17.
Huang, Yuhui, Rut Porta, Kiyoshi Yanagisawa, et al.. (2006). Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis with Selective EP4 Receptor Antagonism. Cancer Research. 66(19). 9665–9672. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marco Rosetti Breakdown of academic impact, for papers by Dianren Xia Breakdown of academic impact, for papers by Dean J. Welsch Breakdown of academic impact, for papers by Xiuling Li Breakdown of academic impact, for papers by Labile Togba Soumaoro Breakdown of academic impact, for papers by Kanae Echizen Breakdown of academic impact, for papers by S. Noura Breakdown of academic impact, for papers by Shigeru Tomozawa Breakdown of academic impact, for papers by Wenjie Zhang Breakdown of academic impact, for papers by Peiyan Hua
Rankless by CCL
2026